Vetbiobank

Vetbiobank is a leading biotech company in the veterinary regenerative medicine sector, with a mission to improve animal healthcare. Founded in 2011, the company specializes in leveraging the unique biological potential of neonatal stem cells to promote healing in animals, particularly dogs, cats, and horses. Vetbiobank's expertise is derived from its founder, a former expert in human cell therapy development, and cord blood-derived stem cells. The company's collaboration with the VetAgro-Sup, a veterinary university in Lyon, France, has been pivotal in developing new therapeutic solutions. Vetbiobank's last investment, a €1.00M venture round, was secured on 10 October 2019 from Paris Business Angels. The company's focus on providing veterinarians with high-quality biological products showcases its commitment to advancing animal wellbeing. With its vision to establish cell therapy products as a first-line treatment in veterinary practice, Vetbiobank is positioned for growth in the biotechnology sector.